The CRC Blueprint

My scientific approach to my own cancer – shared with you.

Already treated

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

Phase 2 · randomised · 110 people · 3 sites in 2 countries · Recruiting now

August 7, 2026
Investigate the Efficacy of Chemotherapy in Patients With Positive ctDNA After Surgery and Adjuvant Chemotherapy for a Stage III Colorectal Cancer

Phase 3 · randomised · 1,660 people · 1 site in France · Recruiting now

August 7, 2026
A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC

Phase 3 · randomised · 280 people · 1 site in China · Recruiting now

August 7, 2026
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Phase 2 · randomised · 768 people · 105 sites in 10 countries · Recruiting now

August 7, 2026
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Phase 2 · 560 people · 54 sites in 7 countries · Recruiting now

August 7, 2026
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

Phase 2 · randomised · 150 people · 10 sites in 2 countries · Recruiting now

August 7, 2026
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer

Phase 3 · randomised · 1,020 people · 21 sites in 6 countries · Recruiting now

August 7, 2026
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Phase 3 · randomised · 400 people · 366 sites in 25 countries · Recruiting now

August 7, 2026
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Phase 3 · randomised · 700 people · 250 sites in 26 countries · Recruiting now

August 7, 2026